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Abstract
Background: Neuroglobin is a hexacoordinated member of the globin family of proteins. It is
predominantly localized to various brain regions and retina where it may play a role in protection
against ischemia and nitric oxide-induced neural injury. Cerebrospinal fluid was collected from 12
chronic regional or systemic pain and 5 control subjects. Proteins were precipitated by addition of
50% 0.2 N acetic acid, 50% ethanol, 0.02% sodium bisulfite. The pellet was extensively digested with
trypsin. Peptides were separated by capillary liquid chromatography using a gradient from 95%
water to 95% acetonitrile in 0.2% formic acid, and eluted through a nanoelectrospray ionization
interface into a quadrapole – time-of-flight dual mass spectrometer (QToF2, Waters, Milford, MA).
Peptides were sequenced (PepSeq, MassLynx v3.5) and proteins identified using MASCOT ®.
Results: Six different neuroglobin peptides were identified in various combinations in 3 of 9 female
pain subjects, but none in male pain, or female or male control subjects.
Conclusion: This is the first description of neuroglobin in cerebrospinal fluid. The mechanism(s)
leading to its release in chronic pain states remain to be defined.
Background
The protein constituents (proteome) of cerebrospinal
fluid (CSF) are altered in disease states such as meningitis,
but may also be more subtly altered in many other neural
conditions. CSF has been difficult to investigate because
of the need for invasive lumbar punctures and the small
volumes of CSF available for analysis. This situation is
now rapidly changing as methods requiring microliter
volumes and sophisticated analysis tools such as pro-
teomics become available [1,2]. Proteomics has made it
possible to identify scores of proteins that have not been
previously discovered in this fluid.
One such protein is neuroglobin. Neuroglobin is a
recently identified member of the globin family. It binds
oxygen with an affinity between that of myoglobin and
hemoglobin [3,4]. Neuroglobin is 151 amino-acids long
with a molecular mass of ≈ 17 kDa. The mouse and
human genes are 94% identical. Neuroglobin is an
ancient protein (estimated < 550 Myr old) that is more
related to the annelid Aphrodite aculeate intracellular
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globin (30% identify) [5] than to vertebrate myoglobin
(<21% identity) and hemoglobin (<25% identity) [3].
Human neuroglobin mRNA is predominantly expressed
in brain with high signal in the frontal lobe, subthalamic
nucleus and thalamus. The concentration is estimated to
be less of 0.01% of the total brain protein content [3].




Five peptides derived from neuroglobin (NCBInr ID
accession 10864065) were identified using both the MAS-
COT software with NCBInr database and ProteinLynx
Global Server with SwissProt database (Table 1). Two pre-
cursor ions with mass/charge (M/Z) ratios of 423.97 and
435.82 were identified in CSF sample #3 with the Swiss-
Prot, but not NCBInr, searches. Table 1 shows the mass-
over-charge (m/z), charge state, elution time, position,
sequence, molecular weight (Mr) for each peptide. The
numbers of matching peptides were 5 in sample #1, 2 in
sample #2, and 3 in sample #3. The peptides mapped
31.1%, 13.9% and 17.2%, respectively, of the total neu-
roglobin protein sequence. They matched amino acids 1–
10 and 15–30 of the N-terminal and 131–151 of the C-
terminal. Trypsin digestion missed cleavage sites at amino
acids 18 and 146. Reproducibility was demonstrated by
the consistent retention times for the same peptides from
different subjects. No low abundance neuroglobin
peptides were found in other samples. BLAST sequence
analysis of all six peptides identified only one protein:
hypothetical 16.9 kDa protein (neuroglobin: NREF and
iProClass NF00135839; SwissProt/TrEMBL Q9NPG2).
Mass Spectrometry
Figures 1 through 5 show the tandem MS data for the 5
[M+H+] precursor ions. The mass of each b- and y-frag-
ment is listed. The amino acid sequence is shown at the
top of each spectrum using the Roepstorff nomenclature
[11]. The amino acid sequences were determined from
both the N- and C-terminal directions. Figures 1 and 4
show two spectra from subject #1. Figures 3 and 5 show
two spectra from subject #2. Figure 2 shows one spectrum
from subject #3. Neuroglobin peptides were detected in 2
of the 3 CapLC runs for subjects #1 and #2, but only in 1
run for subject #3.
The peptides with M/z of 580 and 761 (Table 1) over-
lapped with the 761 ion having a missed tryptic cleavage
point at Arg146. Additional peptides were not identified,
perhaps because we did not reduce disulfide bridges to
reveal additional trypsin digestion sites. However, all the
identified peptides were specific for neuroglobin, and so
were appropriate markers for fast identification of this
protein.
Neuroglobin and Pain Subjects
Neuroglobin-derived peptides were found in 3 of 9 female
pain subjects, but none of the 3 male pain subjects; it was
not detected in the 3 female or 2 male control subjects.
Within the chronic pain group there was no association
between the presence of neuroglobin and clinical factors
such as age, extent or duration of pain, or tenderness to
Table 1: Amino acid sequence of neuroglobin peptides identified from human CSF using CapLC nanoESI Q-TOF tandem mass 
spectrometry.
#a Amino Acids M/z b Zc Molecular Weight ∆d Amino Acid Sequences Timee (min)
Calc. Exp.
1 1–10 423.98 3 1268.65 1268.91 0.25 (-)MERPEPELIR(Q) 37.02
1 15–30 580.73 3 1738.95 1739.18 0.23 (R)AVSRSPLEHGTVLFAR(L) 42.94
1 19–30 442.99 3 1325.71 1325.95 0.25 (R)SPLEHGTVLFAR(L) 42.68
1 131–146 580.04 3 1736.87 1737.10 0.24 (R)AAWSQLYGAVVQAMSR(G) 68.23
1 131–151 761.42 3 2281.06 2281.23 0.17 (R)AAWSQLYGAVVQAMSRGWDGE(-) 74.49
2 131–146 580.02 3 1736.87 1737.03 0.16 (R)AAWSQLYGAVVQAMSR(G) 68.24
2 131–151 761.37 3 2281.06 2281.09 0.03 (R)AAWSQLYGAVVQAMSRGWDGE(-) 74.54
3 1–10 423.97 f 3 1268.65 1268.88 0.23 (-)MERPEPELIR(Q) 37.31
3 15–30 435.82 f 4 1738.95 1739.27 0.32 (R)AVSRSPLEHGTVLFAR(L) 43.27
3 19–30 442.99 3 1325.71 1325.96 0.25 (R)SPLEHGTVLFAR(L) 43.01
a. Subject Number
b. Mass / charge ratio
c. Charge
d. Difference (error) between the experimental (Exp.) and calculated (Calc.) molecular weights
e. Elution time expressed in minutes.
f. Peptides in Subject 3 identified only with ProteinLynx Global Server using the SwissProt database.Proteome Science 2005, 3:2 http://www.proteomesci.com/content/3/1/2
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The tandem mass spectrum is shown for the neuroglobin amino acid 1 to 10 peptide Figure 1
The tandem mass spectrum is shown for the neuroglobin amino acid 1 to 10 peptide. In this and the following figures, the top 
line represents the b-series, and the 2nd line the y-series. The x-axis presents M/z and the y-axis signal intensity. The numbers 
are the M/z values for each daughter ion (vertical lines).
The tandem mass spectrum is shown for the neuroglobin amino acid 15 to 30 peptide Figure 2
The tandem mass spectrum is shown for the neuroglobin amino acid 15 to 30 peptide.Proteome Science 2005, 3:2 http://www.proteomesci.com/content/3/1/2
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The tandem mass spectrum is shown for the neuroglobin amino acid 19 to 30 peptide Figure 3
The tandem mass spectrum is shown for the neuroglobin amino acid 19 to 30 peptide.
The tandem mass spectrum is shown for the neuroglobin amino acid 131 to 146 peptide Figure 4
The tandem mass spectrum is shown for the neuroglobin amino acid 131 to 146 peptide.Proteome Science 2005, 3:2 http://www.proteomesci.com/content/3/1/2
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pressure. No hemoglobin or cytoglobin [12,13] were
detected.
Discussion
This is the first description of neuroglobin protein in the
CSF of any species. Neuroglobin joins cytoglobin (his-
toglobin) in a new globin subfamily that forms hexacoor-
dinated heme iron complexes [12,13]. These are distinct
from the pentacoordinated hemoglobin and myoglobin.
The source of neuroglobin in the CSF is likely to be brain
regions such as the subthalamic nuclei (60% of total brain
neuroglobin mRNA expression), frontal lobe, thalamus,
occipital pole, pituitary gland, and medulla oblongata
[3,14]. Immunohistochemistry confirmed this distribu-
tion with strong staining in the hippocampus, thalamus,
hypothalamus (especially the paraventricular nucleus)
and brainstem nuclei of cranial nerves [15]. Expression
was often patchy within these regions indicating that only
select neurons expressed neuroglobin. Regions with high
sensitivity to hypoxia such as the cerebral cortex had
constitutive expression [15]. Spinal cord was a less likely
source since its neuroglobin mRNA expression was less
than 10% of that from the subthalamic nuclei. Neu-
roglobin mRNA was expressed in the retina [16] and in
peripheral nerves suggesting that the mRNA was axonally
transported and translated to distal neurons [17]. The pro-
tein has a cytoplasmic distribution [18]. Neuroglobin
could provide oxygen for high energy consuming proc-
esses such as synaptic activity, neural plasticity, or efferent
transmitter release as in nociceptive nerve axon responses.
Neuroglobin mRNA was also present in adrenal cells and
the  β cells of the pancreatic islets of Langerhans [14].
Roles in diabetes or hypoxia-induced insulin secretion are
unstudied. These studies of mRNA expression should not
be extrapolated into relative levels of protein expression
or neuroglobin turnover since concordance between
microarray and proteomic studies can be as low at 13%
[19].
Neuroglobin is likely to serve as an intracellular oxygen
depot to facilitate oxygen diffusion to the mitochondria.
A role in oxygen supply was supported by the very high
expression of neuroglobin mRNA in retinal neurons but
not the supporting ocular epithelium and other structures
[16]. Retinal neuroglobin concentrations were estimated
at > 100 µM, compared to > 1 µM for the whole brain. The
retinal and muscle oxygen tensions, oxygen affinities and
tissue concentrations of neuroglobin and myoglobin were
comparable suggesting that the two play homologous
roles in their respective tissues.
Neuroglobin might act in certain circumstances to limit
neural cellular damage during hypoxia. Neuroglobin
expression was inversely correlated to the sensitivity of the
The tandem mass spectrum is shown for the neuroglobin amino acid 131 to 151 peptide Figure 5
The tandem mass spectrum is shown for the neuroglobin amino acid 131 to 151 peptide.Proteome Science 2005, 3:2 http://www.proteomesci.com/content/3/1/2
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brain regions to ischemia [3]. For example, neuroglobin
expression was 4 times higher in the cerebral cortex than
the hippocampus, corresponding to the time for ischemia
to cause half-maximal damage (19.1 and 12.7 min,
respectively) in these tissues [20]. Neuroglobin-immuno-
reactive material was upregulated in the cytoplasm of
neurons that were destined to survive acute cerebral
ischemia, and was reduced in apoptotic neurons [21].
Hypoxic induction of neuroglobin was blocked by the
mitogen-activated protein kinase/extracellular signal-reg-
ulated kinase kinase inhibitor PD98059 [22]. Like hemo-
globin and myoglobin, hemin increased neuroglobin 4-
fold through a separate signalling process mediated by
protein kinase G and soluble guanylate cyclase. Hypoxia-
inducible neuroprotective factor (HIF-1) that can induce
β-globin production may play a role in neuroglobin
induction. It is not clear if there are differential responses
to intermittent, recurrent, or chronic cerebral ischemia.
Neuroglobin was also colocalized with nitric oxide syn-
thase in the lateral tegmental nuclei, stria terminalis,
habencule, nucleus of the tractus solitarius, periaqueduc-
tal grey matter, amygdala and subfornic organ [23]. The
protein may act as a nitric oxide scavenger, a role that has
also recently been proposed for myoglobin [24]. This
function would protect against nitric oxide – induced
damage that is part of hypoxia – ischemia related neuron
injury. Nitric oxide appears to bind to the
hexacoordinated deoxy ferrous form (F8His-Fe2+-E7His)
and displace the protein from the globin [25]. This affinity
may be a double-edged sword, since neuroglobin, hemo-
globin and myoglobin may protect Plasmodium  and
Trypanosoma from the antiparasitic effects of nitric oxide
[26]. Neuroglobin may also play a protective role in car-
bon monoxide poisoning [27].
In this study, neuroglobin was qualitatively identified in
CSF from 3 female subjects with chronic pain conditions.
Females have greater pain sensitivity to pressure and other
stimuli (lower pain thresholds) [28], but pain is not
thought to induce neural hypoxia or any of the known
triggers of neuroglobin expression [21].
It is tempting to speculate that the source of neuroglobin
in our samples was from nuclei involved in pain transmis-
sion or regulation such as the thalamus, prefrontal cortex,
amygdala, or spinal cord dorsal horn somatic pain synap-
tic regions (e.g. layers 1 and 2 of Rexed). The fact that
neuroglobin was not detected in any of the control
females in our study makes it unlikely that the expression
was related to gender. Examination of additional normal
and chronic pain subjects is underway to determine the
factors that may be responsible for neuroglobin expres-
sion. It is also possible that the proteomic detection of
neuroglobin varies depending upon sample preparation,
signal-to-noise ratio for relatively low abundance proteins
compared to albumin and immunoglobulins that are
present in high abundance, duration of storage, factors
related to trypsin digestion, capillary liquid chromatogra-
phy, mass spectrometry or bioinformatic neuroglobin
peptide detection. These technical factors are unlikely to
be significant since our samples were treated identically
and were stored for approximately equal amounts of time.
In contrast to neuroglobin's localization, cytoglobin-
immunoreactive material was localized to the cellular
nucleus in all tissues examined [14]. Mammalian
cytoglobin genes display an unique exon-intron pattern
with an additional exon resulting in a C-terminal exten-
sion of the protein that is not present in lower species such
as zebra fish [29,30]. Again, it is not clear if cytoglobin acts
as an oxygen depot or sink, free radical scavenger, oxygen-
sensor or transcription factor. No evidence for cytoglobin
was found in cerebrospinal fluid suggesting that nuclear
degeneration was not present in any of our subjects.
Conclusion
This is the first description of neuroglobin in cerebrospi-
nal fluid and in humans. Neuroglobin was identified in 3
of 9 female pain subjects. The role(s) for this ancient
oxygen and nitric oxide binding protein in humans, and
potential links to pain, remain to be fully determined.
Methods
After obtaining informed consent, lumbar punctures were
performed on 17 subjects as part of an evaluation of pain
mechanisms. Twelve patients had musculoskeletal pain
and five were healthy control subjects. Cerebrospinal fluid
samples were aliquoted and frozen at -70°C. Lipids and
peptides were extracted from 200 µl of thawed CSF by
adding an equal volume of 50% ethanol, 50% 0.2 N acetic
acid 0.02% sodium bisulfite ("acid-ethanol") [6]. Centri-
fuged pellets were reconstituted in 50 µl of 0.1 M ammo-
nium bicarbonate buffer (pH 7.8) and digested with
trypsin (protein-enzyme ratios of 20:1) at 37°C
overnight. Digested peptides were separated by capillary
liquid chromatography (CapLC, Waters, Milford, MA)
over a Zorbax 18WSB reverse phase column (100 mm ×
0.15 mm inner diameter) (Micro-Tech Scientific, Sunny-
vale, CA) at room temperature for 100 min using a gradi-
ent starting at 95% solvent A (aqueous solution of 0.2%
formic acid) and ending with 95% solvent B (acetonitrile
with 0.2% formic acid). The elution was performed at a
flow-rate of 1 µl/min.
The column eluate was pumped through a nanoelectro-
spray interface into a quadrapole – time of flight (Q-TOF-
2, Waters, Milford, MA) mass spectrometer. MASSLYNX
version 3.5 software was used to control the CapLC and
Q-ToF-2, data acquisition, processing, and determinationProteome Science 2005, 3:2 http://www.proteomesci.com/content/3/1/2
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of peptide sequences. The protein identification was per-
formed with the MASCOT MS/MS ion search software
http://www.matrixscience.com and NCBInr protein data-
base [7,8], and with ProteinLynx Global Server Web
(Waters) with SwissProt database. The BLAST algorithm
was used to compare protein queries to database
sequences (e.g. Protein Information Resource, PIR, http://
www.pir.georgetown.edu) [9,10], proteins derived from
GenBank coding sequences, and PDB atomic coordinates.
Samples were assessed by CapLC-Q-ToF-2 in triplicate. At
least 2 separate peptides from neuroglobin had to identify
in each individual sample to ensure that this protein, and
not a related protein, was present. In an attempt to detect
low abundance expression of neuroglobin peptide ions
that were not selected by MS-MS (false negative results),
all MS data from the appropriate CapLC retention times
were reassessed at high resolution. Positive results (MS
data) were checked to see if ions in MS were present but
not in MS-MS for other pieces. All putative neuroglobin
peptide spectra were sequenced using PepSeq (Waters)
and confirmed by visual inspection.
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